Department of Radio-Oncology, Genolier Swiss Medical Network, Geneva and Genolier, Switzerland.
Crit Rev Oncol Hematol. 2015 Mar;93(3):180-9. doi: 10.1016/j.critrevonc.2014.10.011. Epub 2014 Oct 31.
Neoadjuvant chemotherapy followed by surgery is nowadays used in a significant number of patients presenting with locally advanced breast cancer. Most studies clearly demonstrate that, after mastectomy, local regional recurrences can be observed even when pathologic complete response is achieved after neoadjuvant chemotherapy, especially in patients with large size tumour and unfavourable pathologic factors. Retrospective studies remain the main source of information guiding the selective use of radiotherapy after neoadjuvant chemotherapy and mastectomy. This is one of the reasons why there are still many uncertainties regarding the indications of postmastectomy radiotherapy in this patient population. In addition, the extension of irradiation fields to peripheral lymphatics remains somewhat poorly defined in the literature. Finally combining the assessment of clinical and pathologic factors with the use of biomolecular assays should help oncologists determine with more accuracy which patients should receive post-mastectomy radiotherapy following neoadjuvant chemotherapy.
新辅助化疗后手术目前被广泛应用于治疗局部晚期乳腺癌患者。大多数研究明确表明,即使在新辅助化疗后达到病理完全缓解的情况下,仍可观察到乳腺癌根治术后局部区域复发,尤其是在肿瘤较大且病理因素不良的患者中。回顾性研究仍然是指导新辅助化疗和乳腺癌根治术后放疗选择性应用的主要信息来源。这也是为什么在该患者人群中,仍然存在许多关于乳腺癌根治术后放疗适应证的不确定性的原因之一。此外,文献中对于照射野扩展到外周淋巴结的问题仍存在一定程度的不明确。最后,将临床和病理因素的评估与生物分子检测相结合,应该有助于肿瘤学家更准确地确定哪些患者在新辅助化疗后需要接受乳腺癌根治术后放疗。